5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

✍ Scribed by R. Palumbo; A. Bernardo; M.R. Strada; G. Poggi; C. Teragni; A. Amatu; M. Frascaroli; B. Montagna; F. Sottotetti; G. Bernardo

• Book ID: 119600731
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 48 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)70973-5